SCND · Scientific Industries Inc
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for at least one year after the date the Unaudited Condensed Consolidated Financial Statements are issued. The Company has recorded recurring losses from operations and continued cash outflow from operating activities as a result of its strategic focus on the Bioprocessing Systems Operations, which is still in its start-up stage. Historically the Company has relied on equity financings to support its business operations. For the six months ended June 30, 2026, the Company generated negative cash flows from operations of $1,897,600. The Company has an accumulated deficit of $37,974,000 as of June 30, 2026, and expects to continue to generate negative cash flows from operations in the foreseeable future; however, based on management's current operating plan, the Company expects that the cash generated from the Laboratory Equipment Operations' Genie Division sale during fiscal 2025 (refer to Note 11), plus other incoming cash related to the various post Genie Division-sale agreements and escrow account, is sufficient to support business operations for at least one year from the date of issuance of the Unaudited Condensed Consolidated Financial Statements for the six months ended June 30, 2026; however, there is no assurance that management's current operating plan will be successful.”View the 10-Q filed Aug 14, 2026
2 customers — 49% of revenue (the three months ended June 30, 2026)
“For the three months ended June 30, 2026, two customers accounted for approximately 49% of the Company’s total revenue.”
2 customers — 35% of revenue (the six months ended June 30, 2026)
“For the six months ended June 30, 2026, two customers accounted for approximately 35% of the Company’s total revenue.”
One customer — 10% of revenue (the six months ending June 30, 2025)
“For the six months ending June 30, 2025, one customer accounted for approximately 10% of the Company’s total revenue.”
One customer — 10% of revenue (the three months ending June 30, 2025)
“For the three months ending June 30, 2025, one customer accounted for approximately 10% of the Company’s total revenue.”
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.73M | $5.05M | $4.8M | $11.11M | $11.4M | $9.78M | $7.78M | $10.2M | $8.48M | — | — | — | — | — | — | |
| $4.05M | $3.75M | $2.79M | $6.01M | $5.66M | $4.8M | $3.85M | $5.83M | $5.26M | $5.27M | $5.68M | $4.73M | $4.18M | $4.18M | $3.85M | |
| $1.67M | $1.3M | $2.01M | $5.1M | $5.74M | $4.98M | $3.94M | $4.37M | $3.22M | $2.88M | $3.92M | $3.12M | $2.61M | $2.96M | $2.36M | |
| — | 25.78% | 41.83% | 45.92% | 50.32% | 50.9% | 50.58% | 42.82% | 37.99% | — | — | — | — | — | — | |
| $2.56M | $2.49M | $2.9M | $3.57M | $2.87M | $1.62M | $1.14M | $530.5K | $520.9K | $437.5K | $349K | $392.2K | $426.7K | $450.5K | $375.9K | |
| $2.8M | $3.27M | $4.12M | $5.42M | $5.82M | $4.03M | $2.28M | $1.92M | $1.75M | $1.67M | $1.7M | $1.7M | $1.51M | $1.28M | $1.23M | |
| — | — | — | $51.5K | — | — | — | — | — | — | — | — | — | — | — | |
| $395.1K | $610K | $750.7K | $754K | $688.2K | $251.5K | $160.9K | $257.3K | $305.1K | $355.9K | $428.9K | $434.8K | $262.8K | $178.8K | $185.9K | |
| $8.6M | $9.19M | $10.22M | $14.36M | $13M | $9.68M | $4.6M | $3.59M | $3.23M | $3.04M | $3.67M | $3.14M | $2.73M | $2.45M | $2.32M | |
| -$6.92M | -$7.89M | -$8.22M | -$9.26M | -$7.26M | -$4.71M | -$663.5K | $776.1K | -$5500 | -$160.4K | $245K | -$16.8K | -$118.7K | $507.4K | $36.7K | |
| — | -156.12% | -171.28% | -83.34% | -63.72% | -48.17% | -8.52% | 7.61% | -0.06% | — | — | — | — | — | — | |
| -$6.53M | -$7.28M | -$7.47M | -$8.51M | -$6.58M | -$4.46M | -$502.6K | $1.03M | $299.6K | $195.5K | $673.9K | $418K | $144.1K | $686.2K | $222.6K | |
| — | — | — | — | — | — | $0 | $1500 | $1700 | $2900 | $33.9K | $4200 | $3100 | $4800 | $4600 | |
| — | — | — | — | — | $82.2K | $12.6K | $3400 | $6100 | $10.6K | $6000 | $4300 | $0 | — | $12.8K | |
| $6.18M | $6.11M | $192.8K | $170.1K | — | — | — | — | — | — | — | — | — | — | — | |
| -$744.9K | -$1.78M | -$8.02M | -$9.09M | -$7M | -$4.06M | -$667.4K | $770.2K | $1400 | -$146.8K | $218.9K | -$7300 | -$107K | $520.8K | $61.9K | |
| — | $4600 | $0 | $0 | -$1.35M | -$1.15M | -$436.6K | $124.6K | $161.9K | -$74.2K | $53.3K | -$16K | -$31.7K | $124.4K | -$4200 | |
| -$741.3K | -$1.22M | -$6.45M | -$9.09M | -$5.64M | -$3.67M | -$703.3K | $645.6K | -$160.5K | -$72.6K | $165.6K | $8700 | -$75.3K | $396.4K | $66.1K | |
| — | -24.15% | -134.36% | -81.78% | -49.51% | -37.57% | -9.03% | 6.33% | -1.89% | — | — | — | — | — | — | |
| -$824.4K | -$979.5K | -$6.58M | -$9.06M | — | — | — | $645.6K | -$155.8K | -$77K | $169.8K | $4300 | -$60.6K | $395.4K | $75K | |
| USD/shares | — | — | — | — | -$1.00 | — | -$0.46 | $0.43 | -$0.11 | -$0.05 | $0.11 | $0.01 | -$0.05 | $0.30 | $0.05 |
| USD/shares | -$0.05 | -$0.11 | -$0.61 | -$1.27 | -$1.00 | — | -$0.46 | $0.43 | -$0.11 | -$0.05 | $0.11 | $0.01 | -$0.05 | $0.30 | $0.05 |
| shares | — | — | — | — | — | 3.19M | 1.52M | 1.49M | 1.49M | 1.49M | 1.49M | 1.48M | 1.39M | 1.34M | 1.28M |
| shares | — | 11.34M | 10.5M | 10.15M | 6.64M | 3.19M | 1.52M | 1.51M | 1.49M | 1.49M | 1.49M | 1.48M | 1.39M | 1.34M | 1.29M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 18 similar-size Scientific & Technical Instruments companies (of 38 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Benchtop Laboratory Equipment | $3,753,800 | $3,107,300 | $9,745,400 | $9,981,100 | $2,529,900 |
| Bioprocessing Systems | $1,300,000 | $1,689,800 | $1,366,100 | $1,419,400 | $324,600 |
| Benchtop Laboratory Equipment One | — | $1,118,600 | $1,301,400 | $0 | — |
| Corporate And Other | — | $0 | $0 | $0 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Subscriptions | $115,100 | $67,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Benchtop Laboratory Equipment | -$412,900 | -$871,100 | $720,200 | $1,475,800 |
| Corporate And Other | -$1,349,000 | -$1,536,800 | -$2,228,900 | -$1,650,400 |
| Bioprocessing Systems Two | -$6,128,000 | -$5,808,500 | -$7,751,200 | -$11,369,500 |
| Consolidated Entity | -$7,889,900 | -$8,216,400 | -$9,259,900 | -$11,544,100 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Benchtop Laboratory Equipment | -11% | -28% | 7.4% | 14.8% |